Chlamydia pneumoniae and cardiovascular disease: an evolutionary perspective on infectious causation and antibiotic treatment - PubMed (original) (raw)

Review

. 2000 Jun:181 Suppl 3:S394-401.

doi: 10.1086/315602.

Affiliations

• PMID: 10839723
• DOI: 10.1086/315602

Review

Chlamydia pneumoniae and cardiovascular disease: an evolutionary perspective on infectious causation and antibiotic treatment

P W Ewald et al. J Infect Dis. 2000 Jun.

Abstract

Evolutionary considerations implicate infectious causation of atherosclerosis and help to resolve different risk factors as parts of an overall process of disease causation. An evolutionary approach also provides insight for the timing of research efforts to provide better control of pathogen evolution. In particular, evolutionary considerations emphasize the need to understand the transmissibility of Chlamydia pneumoniae from systemic infections in order to control the evolution of antibiotic resistance.

PubMed Disclaimer

Similar articles

• [Atherosclerosis and Chlamydia pneumoniae].
  Larsen MM, Mørn B, Andersen PL, Østergaard LJ. Larsen MM, et al. Ugeskr Laeger. 2002 Dec 9;164(50):5920-4. Ugeskr Laeger. 2002. PMID: 12553110 Review. Danish.
• [Arteriosclerosis caused by infection? A possible link between Chlamydia pneumoniae and atherosclerosis].
  Persson K, Boman J. Persson K, et al. Lakartidningen. 1998 May 13;95(20):2334-6, 2339-40. Lakartidningen. 1998. PMID: 9630800 Review. Swedish.
• [Chlamydia pneumoniae and arteriosclerosis: an innocent onlooker?].
  Vidal Verdú E. Vidal Verdú E. An Med Interna. 1999 Jul;16(7):329-32. An Med Interna. 1999. PMID: 10481330 Review. Spanish. No abstract available.
• Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis.
  Fong IW. Fong IW. J Infect Dis. 2000 Jun;181 Suppl 3:S514-8. doi: 10.1086/315607. J Infect Dis. 2000. PMID: 10839750 Review.
• Chronic infections and coronary heart disease.
  Smith D, Gupta S, Kaski JC. Smith D, et al. Int J Clin Pract. 1999 Sep;53(6):460-6. Int J Clin Pract. 1999. PMID: 10622075 Review.

Cited by

• Disrupted human-pathogen co-evolution: a model for disease.
  Kodaman N, Sobota RS, Mera R, Schneider BG, Williams SM. Kodaman N, et al. Front Genet. 2014 Aug 25;5:290. doi: 10.3389/fgene.2014.00290. eCollection 2014. Front Genet. 2014. PMID: 25202324 Free PMC article.
• Gene/Environment interaction in atherosclerosis: an example of clinical medicine as seen from the evolutionary perspective.
  Mertens G. Mertens G. Int J Hypertens. 2010 Mar 25;2010:654078. doi: 10.4061/2010/654078. Int J Hypertens. 2010. PMID: 20981301 Free PMC article.
• Evolutionary medicine: its scope, interest and potential.
  Stearns SC. Stearns SC. Proc Biol Sci. 2012 Nov 7;279(1746):4305-21. doi: 10.1098/rspb.2012.1326. Epub 2012 Aug 29. Proc Biol Sci. 2012. PMID: 22933370 Free PMC article. Review.
• Mentholation triggers brand-specific shifts in the bacterial microbiota of commercial cigarette products.
  Malayil L, Chattopadhyay S, Kulkarni P, Hittle L, Clark PI, Mongodin EF, Sapkota AR. Malayil L, et al. Appl Microbiol Biotechnol. 2020 Jul;104(14):6287-6297. doi: 10.1007/s00253-020-10681-1. Epub 2020 May 24. Appl Microbiol Biotechnol. 2020. PMID: 32448997
• Ten questions for evolutionary studies of disease vulnerability.
  Nesse RM. Nesse RM. Evol Appl. 2011 Mar;4(2):264-77. doi: 10.1111/j.1752-4571.2010.00181.x. Epub 2011 Jan 17. Evol Appl. 2011. PMID: 25567972 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information